Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Bought by Bayesian Capital Management LP

Bayesian Capital Management LP raised its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 5.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,000 shares of the medical technology company’s stock after purchasing an additional 1,442 shares during the period. Bayesian Capital Management LP’s holdings in Alphatec were worth $372,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ATEC. Vanguard Group Inc. boosted its stake in shares of Alphatec by 1.8% in the third quarter. Vanguard Group Inc. now owns 4,615,223 shares of the medical technology company’s stock worth $59,859,000 after acquiring an additional 80,101 shares during the last quarter. SG Americas Securities LLC purchased a new position in Alphatec during the fourth quarter worth approximately $316,000. Raymond James & Associates raised its position in Alphatec by 26.3% in the fourth quarter. Raymond James & Associates now owns 14,287 shares of the medical technology company’s stock valued at $216,000 after purchasing an additional 2,975 shares during the period. Raymond James Financial Services Advisors Inc. purchased a new stake in Alphatec in the fourth quarter valued at $202,000. Finally, Arizona State Retirement System raised its position in Alphatec by 20.1% in the fourth quarter. Arizona State Retirement System now owns 26,342 shares of the medical technology company’s stock valued at $398,000 after purchasing an additional 4,412 shares during the period. 66.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Alphatec in a research note on Wednesday, May 8th. Piper Sandler lowered their price objective on Alphatec from $19.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, May 8th. Canaccord Genuity Group reissued a “buy” rating and set a $25.00 target price on shares of Alphatec in a research note on Thursday, July 25th. Stifel Nicolaus cut their target price on Alphatec from $24.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, July 11th. Finally, Morgan Stanley cut their target price on Alphatec from $19.00 to $16.00 and set an “overweight” rating for the company in a research note on Monday, July 15th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.78.

Insider Buying and Selling

In related news, General Counsel Tyson Eliot Marshall sold 50,232 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $10.88, for a total value of $546,524.16. Following the sale, the general counsel now owns 245,638 shares of the company’s stock, valued at approximately $2,672,541.44. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 22.80% of the company’s stock.

Alphatec Stock Down 2.8 %

NASDAQ:ATEC traded down $0.28 during mid-day trading on Wednesday, hitting $9.60. The company had a trading volume of 48,113 shares, compared to its average volume of 1,584,373. The business has a fifty day simple moving average of $10.46 and a 200-day simple moving average of $12.73. The company has a current ratio of 2.39, a quick ratio of 1.49 and a debt-to-equity ratio of 13.63. Alphatec Holdings, Inc. has a 1 year low of $8.66 and a 1 year high of $18.32.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Tuesday, May 7th. The medical technology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $138.48 million for the quarter, compared to analyst estimates of $134.07 million. Alphatec had a negative net margin of 37.45% and a negative return on equity of 1,767.81%. The firm’s revenue was up 26.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.40) earnings per share. As a group, equities analysts expect that Alphatec Holdings, Inc. will post -1.04 EPS for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.